US · FLGT · MEDICAL - DIAGNOSTICS & RESEARCH
Fulgent Genetics, Inc. (FLGT) intrinsic value and stock valuation
$24.12as of 2026-11-21 · Mkt cap 526.26M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Fulgent Genetics, Inc. DCF and intrinsic value
InvestorsCraft values FLGT with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from FLGT’s statements →
Fulgent Genetics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2014–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $322.7M | $283.5M | $289.2M | $619M | $992.6M |
| Operating income | -$-91.1M | -$-73.92M | -$-195.53M | $178.5M | $676M |
| Net income | -$-60.51M | -$-42.71M | -$-167.82M | $143.4M | $507.4M |
| EPSd | -$-1.97M | -$-1.41M | -$-5.64M | $4.63M | $16.4M |
| Operating cash flow | -$-101.64M | $21.1M | $27M | $253.5M | $538.6M |
| Capital expenditure | -$-22.57M | -$-40.31M | -$-22.21M | -$-18.77M | -$-23.84M |
| Free cash flow | -$-124.21M | -$-19.25M | $4.8M | $234.8M | $514.7M |
| Total assets | $1.21B | $1.22B | $1.24B | $1.39B | $1.28B |
| Total debt | $7.68M | $8.47M | $15.3M | $38.9M | $21.3M |
| Net debt | -$-42.52M | -$-46.68M | -$-82.22M | -$-40.57M | -$-143.61M |
| Total equity | $1.11B | $1.13B | $1.13B | $1.27B | $1.17B |
| Cash and short-term investments | $336.1M | $258.1M | $424.2M | $526.2M | $450.5M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $322.7M | $283.5M | $289.2M | $619M | $992.6M |
| Cost of revenue | $191.8M | $176.3M | $184.8M | $252.1M | $215.5M |
| Gross profit | $130.9M | $107.2M | $104.5M | $366.9M | $777.1M |
| Research and development expenses | $53.9M | $48.8M | $41.4M | $28.9M | $24.2M |
| Selling, general and administrative expenses | $160M | $124.4M | $130.5M | $150M | $75.2M |
| Other expenses | $8.03M | $7.96M | $128.1M | $9.47M | $1.71M |
| Operating expenses | $222M | $181.1M | $300M | $188.4M | $101.1M |
| Cost and expenses | $413.8M | $357.4M | $484.7M | $440.4M | $316.6M |
| Interest income | $30.9M | $31.3M | $21.6M | $5.62M | $1.35M |
| Interest expense | $70K | $170K | $490K | $1.01M | $0.00 |
| Depreciation and amortization | $24.1M | $24.9M | $26.1M | $32.7M | $11M |
| Ebitda | -$-45.83M | -$-26.86M | -$-147.45M | $217.7M | $692M |
| Operating income | -$-91.1M | -$-73.92M | -$-195.53M | $178.5M | $676M |
| Total other income/expenses, net | $21.1M | $22M | $21.4M | $5.5M | $5.08M |
| Income before tax | -$-70.03M | -$-51.96M | -$-174.09M | $184M | $681M |
| Income tax expense | -$-8.39M | -$-8.14M | $1.15M | $42.1M | $174.8M |
| Net income | -$-60.51M | -$-42.71M | -$-167.82M | $143.4M | $507.4M |
| Weighted average shares outstanding | $30.8M | $30.2M | $29.8M | $30.1M | $29.4M |
| Weighted average diluted shares outstanding | $30.8M | $30.2M | $29.8M | $31M | $31M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $336.1M | $258.1M | $424.2M | $526.2M | $450.5M |
| Net receivables | $91.6M | $77M | $57.5M | $75.1M | $143.3M |
| Inventory | $10.6M | $8.38M | $5.83M | $4.28M | $12.2M |
| Total current assets | $550.5M | $353.6M | $507.9M | $627.9M | $612M |
| Property, plant and equipment, net | $112.6M | $105.6M | $83.5M | $81.4M | $62.3M |
| Goodwill and intangible assets | $158.4M | $157M | $165.1M | $293.7M | $86.8M |
| Long-term investments | $369.3M | $570.4M | $444M | $339M | $507M |
| Total non-current assets | $663M | $866.4M | $727.5M | $758.2M | $666.8M |
| Total assets | $1.21B | $1.22B | $1.24B | $1.39B | $1.28B |
| Accounts payable | $18.7M | $18.4M | $15.4M | $23.1M | $20.5M |
| Short-term debt | $1.94M | $1.85M | $5.14M | $26.8M | $21.3M |
| Deferred revenue | $31.8M | $29.8M | $25.6M | $14.1M | $34.4M |
| Total current liabilities | $85M | $72.9M | $73M | $88.1M | $105.3M |
| Long-term debt | $5.74M | $6.61M | $10.1M | $12.2M | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $21.8M | $17.9M | $29M | $28.1M | $7.53M |
| Capital lease obligations | $5.24M | $5.56M | $11.1M | $14.9M | $0.00 |
| Total liabilities | $106.8M | $90.8M | $102M | $116.2M | $112.8M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | $530M | $590.5M | $633.2M | $801M | $657.6M |
| Accumulated other comprehensive income (loss) | $7.51M | -$-370K | $1.21M | -$-20.9M | -$-760K |
| Total equity | $1.11B | $1.13B | $1.13B | $1.27B | $1.17B |
| Total investments | $655.2M | $773.3M | $770.7M | $785.8M | $792.6M |
| Total debt | $7.68M | $8.47M | $15.3M | $38.9M | $21.3M |
| Net debt | -$-42.52M | -$-46.68M | -$-82.22M | -$-40.57M | -$-143.61M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-61.63M | -$-43.82M | -$-175.24M | $141.9M | $506.2M |
| Depreciation and amortization | $24.1M | $24.9M | $26.1M | $32.7M | $11M |
| Stock-based compensation | $39.6M | $44.5M | $42.9M | $32.6M | $15.9M |
| Change in working capital | -$-117.63M | -$-7.24M | $2.84M | $2M | -$-2.68M |
| Accounts receivable | -$-23.25M | -$-16.3M | $2.39M | $68.6M | $42.3M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $550K | $3.07M | -$-6.9M | -$-25.34M | -$-12.21M |
| Net cash provided by operating activities | -$-101.64M | $21.1M | $27M | $253.5M | $538.6M |
| Investments in property, plant and equipment | -$-22.57M | -$-40.31M | -$-22.21M | -$-18.77M | -$-23.81M |
| Acquisitions, net | $3.77M | $0.00 | -$-400K | -$-182.68M | -$-61.87M |
| Net cash used for investing activities | $111.4M | -$-58.35M | $38.9M | -$-261.31M | -$-546.55M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $89.5M |
| Common stock repurchased | -$-13.92M | -$-3.12M | -$-27.79M | -$-76.11M | -$-4.16M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-14.79M | -$-4.85M | -$-47.78M | -$-77.14M | $85.4M |
| Net change in cash | -$-4.95M | -$-42.19M | $18M | -$-85.39M | $77.5M |
| Cash at end of period | $50.3M | $55.3M | $97.5M | $79.5M | $164.9M |
| Operating cash flow | -$-101.64M | $21.1M | $27M | $253.5M | $538.6M |
| Capital expenditure | -$-22.57M | -$-40.31M | -$-22.21M | -$-18.77M | -$-23.84M |
| Free cash flow | -$-124.21M | -$-19.25M | $4.8M | $234.8M | $514.7M |
Line items
Line items
Line items
About Fulgent Genetics, Inc.
Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.
- CEO
- Ming Hsieh
- Employees
- 1.34K
- Beta
- 0.89
Explore
Frequently asked questions
What is the intrinsic value of Fulgent Genetics, Inc. (FLGT)?
Fulgent Genetics, Inc. (FLGT) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is FLGT undervalued?
FLGT trades at a price of $24.12 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.